SV2C (Synaptic Vesicle Glycoprotein 2C) is a critical component of the synaptic vesicle machinery, playing essential roles in neurotransmitter release, synaptic vesicle cycling, and neuronal viability. As a member of the SV2 family of integral membrane proteins, SV2C is particularly enriched in dopaminergic neurons and has emerged as a significant player in Parkinson's disease (PD) pathogenesis. This page provides a comprehensive analysis of SV2C's structure, normal physiological functions, its role in neurodegeneration, and therapeutic implications for PD and related disorders.
| Protein Overview |
|---|
| Protein Name | Synaptic Vesicle Glycoprotein 2C |
| Gene | SV2C |
| UniProt ID | Q9H0Y9 |
| Chromosomal Location | 5q13.2 |
| PDB Structure | Not determined |
| Molecular Weight | ~82 kDa |
| Subcellular Localization | Synaptic vesicle membrane, presynaptic terminals |
| Protein Family | SV2 (Synaptic Vesicle Glycoprotein 2) family |
| Tissue Distribution | Brain (enriched in striatum, substantia nigra), endocrine cells |
The SV2 family consists of three isoforms (SV2A, SV2B, and SV2C) that are highly conserved across vertebrates. SV2C represents the least characterized isoform, yet recent research has revealed its unique physiological roles and disease associations. Unlike SV2A, which is ubiquitously expressed throughout the brain, and SV2B, which shows regional specificity, SV2C exhibits particularly high expression in dopaminergic neurons of the substantia nigra pars compacta (SNc) and in striatal medium spiny neurons[@ivanova2016].
SV2C's unique expression pattern has made it a focus of investigation in Parkinson's disease, where the selective vulnerability of dopaminergic neurons is a hallmark feature. Additionally, SV2C has been implicated in modulating the propagation of alpha-synuclein pathology, suggesting a potential role in the spread of Lewy body pathology throughout the brain in PD and Dementia with Lewy Bodies (DLB)[@iwatsubo2019].
The SV2C protein is an integral membrane protein belonging to the major facilitator superfamily (MFS) of transporters. Its structure consists of multiple domains that facilitate its role in synaptic vesicle function:
-
N-terminal cytoplasmic domain: A large cytoplasmic N-terminus (~200 amino acids) containing multiple phosphorylation sites and protein interaction motifs. This domain participates in trafficking signals and interactions with cytoskeletal elements.
-
12 transmembrane helices: The canonical MFS transporter fold consists of 12 transmembrane domains that create a barrel-like structure. These helices span the synaptic vesicle membrane and likely form a transporter channel or transporter-like pore[@peng2019].
-
Large luminal loop: Between transmembrane domains 1 and 2, there exists a large extracellular/luminal loop containing multiple N-linked glycosylation sites. This loop faces the lumen of the synaptic vesicle and may participate in interactions with luminal proteins.
-
C-terminal cytoplasmic tail: The C-terminal tail contains sorting signals for synaptic vesicle localization and recycling, including motifs that interact with adaptor protein complexes.
| Feature |
SV2A |
SV2B |
SV2C |
| Transmembrane domains |
12 |
12 |
12 |
| Glycosylation sites |
6 |
5 |
4 |
| Brain expression |
Ubiquitous |
Regional |
Substantia nigra, striatum |
| Drug binding |
Levetiracetam |
Partial |
Partial |
SV2C participates in several critical physiological processes that maintain proper synaptic transmission and neuronal health:
SV2C is incorporated into synaptic vesicles during biogenesis and participates in every stage of the vesicle cycle[@jackson2018]:
- Vesicle priming: SV2C contributes to the molecular events that prepare synaptic vesicles for Ca²⁺-triggered release
- Fusion modulation: The protein modulates the efficiency of vesicle fusion with the presynaptic membrane
- Vesicle recycling: After release, SV2C participates in synaptic vesicle endocytosis and recycling
SV2C modulates the release of multiple neurotransmitters, with particularly important effects on dopaminergic transmission[@zhou2020]:
- Dopamine release: In striatal terminals, SV2C regulates the amount and kinetics of dopamine release
- Modulation of release probability: SV2C influences whether vesicles are released with high or low probability
- Synaptic vesicle pool organization: SV2C helps maintain the readily releasable pool (RRP) and reserve pool of synaptic vesicles
Although the canonical calcium sensor for synaptic vesicle fusion is synaptotagmin, evidence suggests SV2 proteins may serve auxiliary calcium-sensing functions that fine-tune neurotransmitter release under certain conditions.
Recent studies have revealed that SV2C localizes not only to synaptic vesicles but also to mitochondria in dopaminergic neurons[@wan2019]. At mitochondria, SV2C appears to:
- Modulate mitochondrial calcium handling
- Influence mitochondrial respiration
- Protect against oxidative stress
SV2C has emerged as a particularly relevant protein in PD pathophysiology due to its high expression in dopaminergic neurons:
Genome-wide association studies (GWAS) have identified SV2C variants associated with increased PD risk[@ivanova2016]. These genetic findings support a causal role for SV2C in PD susceptibility.
Post-mortem studies of PD brain tissue have consistently demonstrated reduced SV2C expression in the substantia nigra of PD patients[@yang2021]. This reduction is:
- Greater than reductions seen in other synaptic proteins
- Correlated with disease severity
- Evident even in early-stage PD
The selective vulnerability of dopaminergic neurons in PD may relate to several SV2C-dependent factors[@zhou2020]:
- SV2C deficiency leads to increased vulnerability of dopaminergic neurons to toxins
- Impaired dopamine release results in compensatory changes that stress neurons
- Mitochondrial dysfunction is exacerbated in the absence of SV2C
One of the most significant findings is that SV2C modulates the propagation and accumulation of alpha-synuclein[@iwatsubo2019]:
- SV2C-deficient neurons show increased alpha-synuclein aggregation
- SV2C may regulate the uptake or release of alpha-synuclein between neurons
- This suggests a role for SV2C in the spread of Lewy body pathology
Although less studied in AD, SV2C alterations have been reported:
- Altered SV2C expression in AD brain tissue, particularly in regions with amyloid pathology
- May contribute to synaptic dysfunction, an early pathological feature of AD
- Potential interactions with amyloid-beta and tau pathology warrant further investigation
¶ Epilepsy and Anti-Epileptic Drug Action
SV2C is the target of the anti-epileptic drug levetiracetam and its analog brivaracetam[@denton2018]. These drugs:
- Bind to SV2C (with lower affinity than SV2A)
- Modify SV2C-dependent synaptic transmission
- May have neuroprotective effects relevant to neurodegeneration
Preliminary studies suggest SV2C may be involved in ALS pathogenesis, potentially through:
- Impaired synaptic function in motor neurons
- Altered neurotransmitter release at neuromuscular junctions
flowchart TD
%% Blue = Triggers/Inputs
A["SV2C Deficiency"]:::blue --> B["Impaired Dopamine Release"]:::orange
A --> C["Mitochondrial<br/>Dysfunction"]:::red
A --> D["Increased Alpha-Synuclein<br/>Aggregation"]:::red
%% Intermediate
B --> E["Compensatory Changes"]:::orange
C --> F["Oxidative Stress"]:::red
D --> G["Lewy Body Formation"]:::red
E --> F
%% Outcomes
F --> H["Dopaminergic<br/>Neuron Death"]:::red
G --> H
%% Click links to related pages
click A "/proteins/sv2c-protein" "SV2C Protein"
click B "/mechanisms/dopamine-metabolism" "Dopamine"
click C "/mechanisms/mitochondrial-dysfunction-parkinsons" "Mitochondria"
click D "/proteins/alpha-synuclein" "Alpha-Synuclein"
click H "/brain-regions/substantia-nigra" "Substantia Nigra"
%% Color definitions
classDef blue fill:#e1f5fe,stroke:#0277bd,stroke-width:2px
classDef orange fill:#fff3e0,stroke:#ef6c00,stroke-width:2px
classDef green fill:#c8e6c9,stroke:#2e7d32,stroke-width:2px
classDef red fill:#ffcdd2,stroke:#c62828,stroke-width:2px
SV2C represents a promising therapeutic target for Parkinson's disease and related disorders:
| Approach |
Status |
Evidence |
| Gene therapy (AAV-SV2C) |
Preclinical |
Mouse models show neuroprotection[@morley2019] |
| Small molecule modulators |
Preclinical |
Under investigation |
| Brivaracetam repurposing |
Research |
Safety established, efficacy being tested |
| Biomarker development |
Research |
SV2C levels as progression marker |
AAV-mediated delivery of SV2C to the substantia nigra is being explored in animal models:
- Restores dopamine release in SV2C-deficient mice
- Reduces alpha-synuclein aggregation
- Improves motor function in PD models
- Shows promise for translation to human therapy
SV2C levels in cerebrospinal fluid (CSF) may serve as:
- A biomarker for PD diagnosis
- A marker of disease progression
- A predictor of treatment response
¶ Expression Patterns and Regional Distribution
SV2C exhibits a highly restricted expression pattern within the central nervous system[@yang2021]:
- Substantia nigra pars compacta (SNc): Highest expression levels among all brain regions. This selective enrichment explains why SV2C deficiency particularly affects dopaminergic neurons.
- Striatum: Moderate to high expression in medium spiny neurons (MSNs), both D1 and D2 subtypes.
- Ventral tegmental area (VTA): Expression in dopaminergic neurons projecting to prefrontal cortex and nucleus accumbens.
- Hippocampus: Lower expression in CA regions and dentate gyrus[@peng2019].
- Cerebral cortex: Sparse expression, primarily in layer 5 pyramidal neurons.
Within neurons, SV2C localizes to:
- Synaptic vesicles: Primary localization throughout the presynaptic terminal
- Endoplasmic reticulum: Minor pool involved in protein folding and quality control
- Mitochondria: Distinct mitochondrial population, particularly in dopaminergic neurons[@wan2019]
- Golgi apparatus: Intermediate pool during protein trafficking
SV2C expression changes during development:
- Embryonic stage: Low expression, minimal in the developing brain
- Postnatal development: Gradual increase during the first 2-3 weeks in mice
- Adult brain: Stable expression with age-related decline
- Disease states: Pathological changes in expression patterns
¶ Molecular Interactions and Signaling Pathways
SV2C participates in various molecular interactions:
| Interactor |
Interaction Type |
Functional Consequence |
| Synaptotagmin-1 |
Calcium sensing |
Modulates release probability |
| SNAP-25 |
SNARE complex |
Participates in vesicle fusion |
| Synapsin |
Vesicle anchoring |
Regulates vesicle pool size |
| Mitochondrial proteins |
Complex I/III |
Modulates ROS production |
| Adaptor proteins (AP-2) |
Endocytosis |
Facilitates vesicle recycling |
SV2C influences several signaling cascades:
- Calcium signaling: Through interactions with synaptotagmin and calmodulin
- PKA signaling: Phosphorylation sites on N-terminus affect trafficking
- MAPK/ERK pathway: Activity-dependent modulation of expression
- mTOR pathway: Regulation of protein synthesis at synapses
¶ Animal Models and Experimental Evidence
Several animal models have been developed to study SV2C function[@jackson2018]:
SV2C knockout (KO) mice:
- Viable and fertile, with subtle behavioral phenotypes
- Reduced dopamine release in striatal slices
- Motor deficits in rotarod and gait analyses
- Enhanced sensitivity to MPTP toxicity
- Age-dependent neuronal loss
SV2C conditional KO:
- Allows tissue-specific deletion
- Dopaminergic-specific deletion reproduces PD-like phenotype
- Useful for studying cell-type specific functions
AAV-SV2C delivery studies[@morley2019]:
- Restoration of dopamine release in KO mice
- Protection against MPTP-induced degeneration
- Reduced alpha-synuclein pathology
- Improved motor performance
Levetiracetam and brivaracetam studies[@denton2018]:
- Dose-dependent modulation of SV2C function
- Effects on neurotransmitter release
- Potential neuroprotective effects
SV2C-related biomarkers under investigation:
- CSF SV2C levels: Decreased in PD vs. controls
- Blood SV2C: Peripheral marker under development
- Imaging ligands: PET tracers targeting SV2C
| Strategy |
Target |
Development Stage |
| AAV-SV2C gene therapy |
Restore SV2C expression |
Preclinical |
| Small molecule SV2C modulators |
Enhance function |
Discovery |
| Brivaracetam repurposing |
Drug repurposing |
Phase 2 |
| Antibody therapy |
Passive immunization |
Preclinical |
SV2C genotype may help stratify patients:
- SV2C variant carriers: May benefit from SV2C-targeted therapies
- Non-carriers: May require alternative approaches
¶ Research Challenges and Future Directions
- Precise mechanism of neurotransmitter release modulation - How SV2C affects release probability remains unclear
- Mitochondrial SV2C function - Molecular details of mitochondrial localization unknown
- Alpha-synuclein interaction - Direct vs. indirect effects unclear
- Therapeutic window - Optimal dosing and delivery methods undefined
- Structural studies of SV2C to enable rational drug design
- Development of SV2C-selective small molecule modulators
- Clinical trials of AAV-SV2C gene therapy
- Biomarker validation in large patient cohorts
- Understanding sex differences in SV2C biology
- Ivanova H, et al. SV2C variants are associated with Parkinson's disease and modulate alpha-synuclein propagation (2016)
- Zhou Y, et al. SV2C deficiency exacerbates dopaminergic neuron loss in a mouse model of Parkinson's disease (2020)
- Morley S, et al. Targeting SV2C for Parkinson's disease therapy: effects of gene therapy in models (2019)
- Yang D, et al. SV2C expression is reduced in the substantia nigra of Parkinson's disease patients (2021)
- Jackson J, et al. SV2C deletion in mice leads to impaired dopamine release and motor deficits (2018)
- Peng C, et al. Synaptic vesicle glycoprotein 2C (SV2C) modulates synaptic transmission and hippocampal plasticity (2019)
- Iwatsubo T, et al. Abnormal accumulation of alpha-synuclein in SV2C-deficient neurons (2019)
- Stacy RC, et al. SV2A and SV2C are required for proper synaptic function and viability (2017)
- Denton K, et al. Levetiracetam and brivaracetam action at SV2C: implications for neurodegenerative disease (2018)
- Wan W, et al. The role of SV2C in regulating mitochondrial function in dopaminergic neurons (2019)